Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Institute on Drug Abuse (NIDA) |
---|---|
Information provided by: | National Institute on Drug Abuse (NIDA) |
ClinicalTrials.gov Identifier: | NCT00875836 |
Marijuana is the most commonly used illicit drug, yet few clinical trials have evaluated pharmacotherapy treatments for marijuana dependence. This study will evaluate the efficacy of buspirone for reducing marijuana use in marijuana-dependent adults. A contingency management (CM) intervention and motivational enhancement therapy (MET) will be incorporated to encourage study engagement and retention. It is hypothesized that buspirone combined with MET and CM will reduce the percent of marijuana-positive urine drug screen results in marijuana-dependent individuals as compared to a placebo treatment combined with MET and CM.
Condition | Intervention | Phase |
---|---|---|
Marijuana Dependence |
Drug: Buspirone Drug: Placebo |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study |
Estimated Enrollment: | 176 |
Study Start Date: | September 2009 |
Estimated Primary Completion Date: | May 2014 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Buspirone
|
Drug: Buspirone
30 mg capsules twice daily
|
2: Placebo Comparator
Placebo
|
Drug: Placebo
30 mg capsules twice daily
|
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Kathleen White, BS | 843-792-1433 |
United States, South Carolina | |
Medical University of South Carolina | |
Charleston, South Carolina, United States, 29425 |
Principal Investigator: | Aimee McRae-Clark, Pharm.D. | Medical University of South Carolina |
Responsible Party: | Medical University of South Carolina ( Aimee McRae-Clark ) |
Study ID Numbers: | R01DA026782, R01DA026782 |
Study First Received: | April 2, 2009 |
Last Updated: | April 2, 2009 |
ClinicalTrials.gov Identifier: | NCT00875836 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Marijuana Buspirone Contingency management Motivational enhancement therapy |
Serotonin Agonists Buspirone Neurotransmitter Agents Tranquilizing Agents Mental Disorders Psychotropic Drugs |
Substance-Related Disorders Central Nervous System Depressants Disorders of Environmental Origin Anti-Anxiety Agents Marijuana Abuse Serotonin |
Serotonin Agonists Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants Disorders of Environmental Origin Marijuana Abuse |
Pharmacologic Actions Buspirone Serotonin Agents Mental Disorders Therapeutic Uses Substance-Related Disorders Anti-Anxiety Agents Central Nervous System Agents |